Clinical Trials on Estrogen Receptor-positive Breast Cancer in Japan
Total 214 results
-
Osaka Medical CollegeTerminatedBreast Cancer | HER-2 Positive Breast Cancer | Estrogen Receptor Negative NeoplasmJapan
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Toshihiko KonoUnknown
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
Kyoto Breast Cancer Research NetworkPfizerCompletedHormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleTaiwan, Japan, Korea, Republic of, Australia, Hong Kong
-
AstraZenecaActive, not recruitingHormone Receptor Positive Breast CancerCanada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
-
Toshihiko KonoUnknownSelective Estrogen Receptor Modulator (SERM)Japan
-
Osaka Medical CollegeCompletedBreast Cancer | Effects of Chemotherapy | HER-2 Positive Breast CancerJapan
-
National Cancer Center, JapanH.U. Group Research Institute G.K.RecruitingHER2-positive Breast CancerJapan
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States, Japan
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Eisai Co., Ltd.Completed
-
TakedaCompletedPremenopausal Breast CancerJapan
-
Tokyo Medical UniversityTokyo University; Saint Luca International HospitalCompleted
-
AstraZenecaCompletedNeoplasms | Breast Cancer | Metastatic CancerJapan
-
Nippon Kayaku Co., Ltd.CompletedBreast Cancer Nos Metastatic RecurrentJapan
-
Eli Lilly and CompanyCompletedBreast Cancer | Metastatic Breast CancerJapan
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Tokyo Medical and Dental UniversityRecruitingBreast Cancer | Metastatic Breast Cancer | OligometastasisJapan
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Okayama UniversityMerck Sharp & Dohme LLCRecruitingBreast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast CarcinomaJapan
-
Chugai PharmaceuticalCompleted
-
Japanese Foundation for Cancer ResearchChugai PharmaceuticalActive, not recruiting
-
Kyoto Breast Cancer Research NetworkCompleted
-
AgendiaOsaka General Medical CenterCompleted
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerJapan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalCompletedMetastatic Breast CancerJapan
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico
-
Kyoto Prefectural University of MedicineActive, not recruiting
-
Comprehensive Support Project for Oncology ResearchCompleted
-
AstraZenecaCompleted
-
Kyoto Breast Cancer Research NetworkTerminated
-
Eisai Co., Ltd.CompletedBreast Cancer | HER2-negative Breast CancerJapan
-
Tokyo UniversityHuman Genome Center, Institute of Medical Science, University of TokyoTerminated
-
Tokyo UniversityHuman Genome Center, Institute of Medical Science, University of TokyoTerminated
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
-
AstraZenecaCompleted
-
Anwar Ali Ahmad AlameerCompletedEffect of Health Education Regarding Screening Tools of Breast CancerSaudi Arabia
-
Novartis PharmaceuticalsCompletedCastration-resistant Prostate Cancer, Advanced Breast CancerJapan